Mutant p53 achieves function by regulating EGR1 to induce epithelial mesenchymal transition.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Epithelial-mesenchymal transition (EMT) is critical for lung cancer metastasis.
• Non-small cell lung cancer (NSCLC) with p53 mutations shows increased metastatic potential.
• The specific role of the p53-R273H mutation in metastasis requires further elucidation.

Purpose of the Study:

• To investigate the role of the p53-R273H mutation in promoting lung cancer metastasis.
• To elucidate the molecular mechanisms by which p53-R273H influences EMT and invasion.
• To identify potential therapeutic targets for p53-R273H-driven lung cancer.

Main Methods:

• Established a H1299 cell model expressing the p53-R273H mutation.
• Utilized CCK-8, wound healing, and Transwell assays to assess cell proliferation, migration, and invasion.
• Employed Western blot, immunofluorescence, and ChIP-PCR to analyze protein expression and gene regulation.

Main Results:

• The p53-R273H mutation significantly enhanced cell proliferation, migration, invasion, and EMT.
• Expression of EGR1 was upregulated in cells with the p53-R273H mutation.
• Knocking out EGR1 inhibited EMT progression, and p53-R273H was found to bind the EGR1 promoter.

Conclusions:

• The p53-R273H mutation drives lung cancer progression and metastasis by activating EGR1.
• This p53-R273H-EGR1 signaling axis represents a novel therapeutic target for NSCLC.
• Understanding this mechanism provides insights into p53 mutation-driven cancer development.